NASDAQ:JUGG Jaws Juggernaut Acquisition (JUGG) Stock Price, News & Analysis → Jim Cramer’s “The Biggest Drug Ever” (From Behind the Markets) (Ad) Free JUGG Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.33▼$10.3350-Day Range$10.29▼$10.3452-Week Range$9.70▼$10.70Volume500 shsAverage Volume124,978 shsMarket Capitalization$356.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Jaws Juggernaut Acquisition alerts: Email Address Ad Behind the MarketsJim Cramer’s “The Biggest Drug Ever”This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.Unlock the details of this groundbreaking opportunity here... About Jaws Juggernaut Acquisition Stock (NASDAQ:JUGG)JAWS Juggernaut Acquisition Corporation does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities in the wireless communications and related technology/product/service businesses. The company was incorporated in 2020 and is based in Miami Beach, Florida.Read More Ad Behind the MarketsJim Cramer’s “The Biggest Drug Ever”This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.Unlock the details of this groundbreaking opportunity here... JUGG Stock News HeadlinesNovember 8, 2023 | yahoo.comChuck Todd: Elections lay bare the party blind spots the rest of us seeOctober 7, 2023 | mirror.co.ukPrettyLittleThing playsuit has jaws dropping as shoppers say you might as well be nakedApril 26, 2024 | Behind the Markets (Ad)Jim Cramer’s “The Biggest Drug Ever”This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.June 8, 2023 | finance.yahoo.comJAWS Juggernaut Acquisition Corporation Announces Redemption of Class A Ordinary SharesApril 25, 2023 | wsj.comJaws Juggernaut Acquisition Corp. Cl AApril 1, 2023 | wsj.comJaws Hurricane Acquisition Corp.March 23, 2023 | seekingalpha.comJUGGW Jaws Juggernaut Acquisition Corporation WT EXP 061726March 14, 2023 | morningstar.comJaws Juggernaut Acquisition Corp Units (1 Ord Share Class A & 1/4 War) JUGGU Stock QuoteApril 26, 2024 | Behind the Markets (Ad)Jim Cramer’s “The Biggest Drug Ever”This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.March 1, 2023 | dailymail.co.ukMichael B. Jordan drops jaws as he showcases his sculpted body in sizzling new Calvin Klein campaignNovember 19, 2022 | finance.yahoo.comWith 64% institutional ownership, Jaws Juggernaut Acquisition Corporation (NASDAQ:JUGG) is a favorite amongst the big gunsAugust 13, 2022 | investing.comJaws Juggernaut Acquisition Corp (JUGG)May 4, 2022 | seekingalpha.comBio-Techne Corporation (TECH) CEO Chuck Kummeth On Q3 2022 Results - Earnings Call TranscriptMay 3, 2022 | finance.yahoo.comWhat You Need To Know About Jaws Juggernaut Acquisition Corporation's (NASDAQ:JUGG) Investor CompositionApril 1, 2022 | finance.yahoo.comWhat Type Of Shareholders Make Up Jaws Juggernaut Acquisition Corporation's (NASDAQ:JUGG) Share Registry?See More Headlines Receive JUGG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jaws Juggernaut Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorFinancial Services Industry Shell Companies Sub-IndustryN/A Current SymbolNASDAQ:JUGG CUSIPN/A CIK1842609 Webjawsspac.com Phone203-422-7718FaxN/AEmployees2,021Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$12.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-85.46% Return on Assets3.65% Debt Debt-to-Equity RatioN/A Current Ratio0.21 Quick Ratio0.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.37 per share Price / Cash Flow28.04 Book Value($0.31) per share Price / Book-33.32Miscellaneous Outstanding Shares34,500,000Free FloatN/AMarket Cap$356.39 million OptionableNot Optionable Beta0.03 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Paul E. Jacobs Ph.D. (Age 60)CEO & Director Mr. Michael Racich (Age 51)Chief Financial Officer Mr. Wilcoln Lee (Age 47)Chief Investment Officer Key CompetitorsInflection Point Acquisition Corp. IINASDAQ:IPXXNabors Energy Transition Corp. IINASDAQ:NETDTortoiseEcofin Acquisition Corp. IIINYSE:TRTLBattery Future AcquisitionNYSE:BFACAlchemy Investments Acquisition Corp 1NASDAQ:ALCYView All Competitors This page (NASDAQ:JUGG) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressThe only accurate crypto trading system I know …Weiss RatingsThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jaws Juggernaut Acquisition Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
